The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Increasing patient access to the latest treatments
Solange Peters, MD, PhD from the University of Lausanne, Lausanne, Switzerland discusses the current treatment landscape of advanced non-small cell lung cancer (NCSLC) at the annual meeting of European Lung Cancer Conference (ELCC) 2017 in Geneva, Switzerland. Dr Peters talks about the importance of genetic screening of patients which could lead to more informed treatment decisions. It is also extremely crucial for clinicians to ensure that patients worldwide have access to the latest diagnosis and treatment methods as without this, the advantages and cost of research to develop the treatment methods is not being exploited in its entirety.
